The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Piggybacked by PEGylation?

  • Shin, Kichul (Division of Rheumatology, Seoul Metropolitan Government-Seoul National University Boramae Medical Center)
  • Received : 2018.10.11
  • Accepted : 2018.10.18
  • Published : 2018.11.01
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Smolen JS, Landewe R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017;76:960-977. https://doi.org/10.1136/annrheumdis-2016-210715
  2. Kaushik VV, Moots RJ. CDP-870 (certolizumab) in rheumatoid arthritis. Expert Opin Biol Ther 2005;5:601-606. https://doi.org/10.1517/14712598.5.4.601
  3. Ruiz Garcia V, Burls A, Cabello JB, Vela Casasempere P, Bort-Marti S, Bernal JA. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. Cochrane Database Syst Rev 2017;9:CD007649.
  4. Kang YM, Park YE, Park W, et al. Rapid onset of efficacy predicts response to therapy with certolizumab plus methotrexate in patients with active rheumatoid arthritis. Korean J Intern Med 2018;33:1224-1233. https://doi.org/10.3904/kjim.2016.213
  5. Keystone E, Heijde Dv, Mason D Jr, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008;58:3319-3329. https://doi.org/10.1002/art.23964
  6. Kumar N, Naz S, Quinn M, Ryan J, Kumke T, Sheeran T. Treatment of rheumatoid arthritis with certolizumab pegol: results from PROACTIVE, a non-interventional study in the UK and Ireland. Adv Ther 2018;35:1426-1437. https://doi.org/10.1007/s12325-018-0758-1
  7. Weinblatt ME, Fleischmann R, van Vollenhoven RF, et al. Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population. Arthritis Res Ther 2015;17:325. https://doi.org/10.1186/s13075-015-0841-9
  8. Ebina K, Hashimoto M, Yamamoto W, et al. Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis: the ANSWER cohort study. PLoS One 2018;13:e0194130. https://doi.org/10.1371/journal.pone.0194130
  9. Bluett J, Barton A. Precision medicine in rheumatoid arthritis. Rheum Dis Clin North Am 2017;43:377-387. https://doi.org/10.1016/j.rdc.2017.04.008